Schering/Biogen interferon suit

Executive Summary

Biogen will receive $45 mil.-$50 mil. from Schering-Plough as part of interferon alpha royalty arbitration settlement. Royalty payments on U.S. sales for Intron A, Rebetron, Rebetol and PEG-Intron will recommence Oct. 1. Schering's payment "represents a portion of the amount that was in dispute between the parties," Biogen said. "The actual amount of the payment is subject to final calculation and review." Schering ceased royalty payments to Biogen in January 2001 following a favorable appeals court decision on the scope of Biogen's patents...